陆小龙, 李龙飞, 李平平, 梁万徽, 苏梦, 左池靖, 张静, 王茜, 张云静, 彭灿. 基于UPLC-Orbitrap-HRMS结合网络药理学分析心痛舒喷雾剂入血成分及治疗急性心肌梗死的作用机制J. 药学学报, 2025, 60(10): 3157-3168. DOI: 10.16438/j.0513-4870.2025-0142
引用本文: 陆小龙, 李龙飞, 李平平, 梁万徽, 苏梦, 左池靖, 张静, 王茜, 张云静, 彭灿. 基于UPLC-Orbitrap-HRMS结合网络药理学分析心痛舒喷雾剂入血成分及治疗急性心肌梗死的作用机制J. 药学学报, 2025, 60(10): 3157-3168. DOI: 10.16438/j.0513-4870.2025-0142
LU Xiao-long, LI Long-fei, LI Ping-ping, LIANG Wan-hui, SU Meng, ZUO Chi-jing, ZHANG Jing, WANG Qian, ZHANG Yun-jing, PENG Can. Exploring the blood-entry elements of Xintongshu spray and its mechanism of action in treating acute myocardial infarction using UPLC-Orbitrap-HRMS and network pharmacologyJ. Acta Pharmaceutica Sinica, 2025, 60(10): 3157-3168. DOI: 10.16438/j.0513-4870.2025-0142
Citation: LU Xiao-long, LI Long-fei, LI Ping-ping, LIANG Wan-hui, SU Meng, ZUO Chi-jing, ZHANG Jing, WANG Qian, ZHANG Yun-jing, PENG Can. Exploring the blood-entry elements of Xintongshu spray and its mechanism of action in treating acute myocardial infarction using UPLC-Orbitrap-HRMS and network pharmacologyJ. Acta Pharmaceutica Sinica, 2025, 60(10): 3157-3168. DOI: 10.16438/j.0513-4870.2025-0142

基于UPLC-Orbitrap-HRMS结合网络药理学分析心痛舒喷雾剂入血成分及治疗急性心肌梗死的作用机制

Exploring the blood-entry elements of Xintongshu spray and its mechanism of action in treating acute myocardial infarction using UPLC-Orbitrap-HRMS and network pharmacology

  • 摘要: 为探明心痛舒喷雾剂治疗急性心肌梗死(acute myocardial infarction, AMI) 的潜在活性成分及作用机制, 采用超高效液相色谱-四极杆-静电场轨道阱高分辨质谱法(UPLC-Orbitrap-HRMS) 在正、负离子模式下检测, 分析鉴定心痛舒喷雾剂的入血原型成分与代谢产物, 结果共鉴定出41个入血原型成分, 其中有苯酞类16个、有机酚酸类15个、单萜类4个、苯乙酮类3个、香豆素类2个、糖类1个; 鉴定出46个代谢产物, 其中有22个苯酞类相关代谢产物、16个有机酚酸类相关代谢产物、苯乙酮类相关代谢产物7个、单萜类相关代谢产物1个。并结合网络药理学分析, 预测心痛舒喷雾剂入血成分治疗急性心肌梗死的作用靶点和信号通路, 结果表明, 有机酚酸类、苯酞类、单萜类为心痛舒喷雾剂治疗AMI的主要活性成分, 通过调控PI3K/Akt通路、AGE-RAGE通路、MAPK通路来治疗AMI。分子动力学模拟结果表明, 靶点蛋白与活性成分具有较好的结合能力。所有实验动物的使用取得了安徽中医药大学实验动物道德伦理委员会的批准(批准号: AHUCM-rats-2021105)。

     

    Abstract: In order to investigate the potential active components and mechanism of action of Xintongshu Spray (XTS) in the treatment of acute myocardial infarction (AMI), ultra performance liquid chromatography-quadrupole-electrostatic field orbital trap high-resolution mass spectrometry (UPLC-Orbitrap-HRMS) was used to analyze and identify the blood-entry prototype components and metabolites of XTS in both positive and negative ion modes. A total of 41 blood-entry prototype components and metabolites were identified, including 16 phthalides, 15 organic phenolic acids, 4 monoterpenes, 3 acetophenones, 2 coumarins, and 1 sugar; 46 metabolites were identified, including 22 phthalide-related metabolites, 16 organic phenolic acids, 7 acetophenone-related metabolites, and 1 monoterpene-related metabolite. Combined with network pharmacological analysis, the target of action and signaling pathway of XTS into blood components for the treatment of AMI were predicted. The results showed that organic phenolic acids, phthalides, monoterpenes are the main active components of XTS for AMI, through the regulation of PI3K/Akt pathway, AGE-RAGE pathway, MAPK pathway to treat AMI. The results of molecular dynamics simulation showed that that the target proteins have good binding ability with the active ingredients. The use of all experimental animals has been approved by the Ethics Committee of Laboratory Animal of Anhui University of Traditional Chinese Medicine (AHUCM-rats-2021105).

     

/

返回文章
返回